Table 1.
Patient characteristics
| Characteristics | n = 21 |
|---|---|
| Age | Median 68 (38–84) |
| Gender | |
| Male | 12 (57%) |
| Female | 9 (43%) |
| Primary tumour location | |
| Right | 9 (43%) |
| Left | 12 (57%) |
| Resection | |
| Concurrent | 5 (24%) |
| Subsequent – liver first | 5 (24%) |
| Subsequent – primary first | 11 (52%) |
| Time between resections | Median 36 days |
| Treatment | |
| Chemonaïve | 11 (52%) |
| Both tumours | 7 (33%) |
| Only metastasis | 2 (10%) |
| Only primary | 1 (5%) |
| Neoadjuvant treatment | |
| CAPOX | 2 (10%) |
| CAPOX + bevacizumab | 2 (10%) |
| FOLFIRI + cetuximab | 1 (5%) |
| FOLFOX + cetuximab | 2 (10%) |
| Between resections | |
| CAPOX | 2 (10%) |
| FOLFOX | 1 (5%) |
| Number metastases | Median 2 (1–5) |
| Microsatellite stability | 21 (100%) |
| Tumour stage | |
| Stage IV | 21 (100%) |
| Tumour differentiation | |
| Low | 2 (10%) |
| High | 19 (90%) |
CAPOX denotes capecitabine and oxaliplatin, FOLFIRI signifies 5-fluorouracil and irinotecan; and FOLFOX indicates 5-fluorouracil and oxaliplatin